EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

Standard at Scale, Personal at the Point of Care: Designing Software That Serves ABA

In this episode of the EarliPoint Exchange, Dr. Cheryl Tierney and Kirsten Yurich, BCBA, are joined by Dr. Kerri Milyko, PhD, BCBA-D, Vice President of Clinical Development at Centria Autism. Drawing from a career that spans Precision Teaching, university teaching, and her work building CR Elements at CentralReach (an online curriculum), Dr. Milyko now leads clinical systems for one of the largest ABA providers in the country. She brings a rare dual lens: clinician and product builder, small-business operator and large-organization leader.

This conversation digs into two challenges every ABA organization is wrestling with right now: how to design and use software and systems that genuinely align with care delivery best practices, and how to bring standardization to ABA at scale without sacrificing the individualization that defines the work. Dr. Milyko shares what gets standardized, what stays personalized, where technology helps, where it gets in the way, and what it takes to keep clinical integrity intact as organizations grow. Listeners will leave with a sharper framework for evaluating ABA tech, building internal systems, and defending high-quality care to funders, families, and field teams.

The webinar will be held on July 14, 2026, from 12PM-1PM, and includes 1 BACB® GEN CEU. Attendance is included free with a BehaviorLive subscription, and registrants will also have access to the recorded session on-demand for CEUs.

Learning Objectives

  • Describe how product and software design can be aligned with established ABA clinical best practices to support consistent, ethical care delivery.
  • Identify strategies and benefits for standardizing clinical workflows and decision-making across large ABA organizations while preserving individualized, person-centered care.
  • Explain how outcome data, instructional design, and behavior-analytic principles can be embedded in software and systems to support clinicians at the point of care.
  • Evaluate the trade-offs, guardrails, and ethical considerations in scaling ABA practices (with or without technology)

Register now to reserve your spot and explore how groundbreaking research in eye-tracking is advancing the future of autism diagnosis and assessment.

Pete Polgar

VP of Marketing

Pete Polgar is the Vice President of Marketing at Earlipoint. He leads the company’s marketing strategy, focusing on brand positioning, demand generation, and digital growth. With a background in performance marketing and content strategy, Pete works on aligning marketing initiatives with business development to drive measurable results and expand Earlipoint’s market presence.

Latest News

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder